Download MendeleyTPP-45142-an Anti-HER2 T cell Engager-Designed for Selective HER2-Low Cancer Immunotherapy.
De Tavernier, E., Kim, P.S., Bruch, E.M., Cortez-Retamozo, V.F., Timmerman, L., Flynn, A.L., Van Overbeke, W., Tirode, F., Cintra Barbosa-Lorenzi, V., Piepenhagen, P., Dinh-Le, T., Luna, E., Li, A., Baker, A., Rak, A., Pao, L.I., Vintem, A.P.B.(2026) Mol Cancer Ther
- PubMed: 41504346
- DOI: https://doi.org/10.1158/1535-7163.MCT-25-0654
- Primary Citation of Related Structures:
9MTE, 9MTX - PubMed Abstract:
The standard of care for patients with HER2-positive cancers is well established, but a significant unmet need exists for patients with HER2-low tumors, who do not meet the eligibility criteria for trastuzumab, and for patients with HER2-positive tumors, who are refractory to trastuzumab treatment. Therefore, in this study, we developed a NANOBODY® domain-based HER2-targeting, T cell receptor (TCR)αβ-based T cell engager (TCE) molecule-TPP-45142; it recognizes a HER2 epitope distinct from that recognized by trastuzumab and pertuzumab and redirects T cells to kill HER2-low cancers such as breast, gastric, and gastroesophageal junction adenocarcinoma (GEJ) cancers. TPP-45142 mediated potent T cell-dependent cytotoxicity against HER2-low cancer cell lines in vitro and inhibited in vivo tumor growth of HER2-low breast cancer xenografts. TPP-45142 was highly selective toward tumor cells expressing low HER2 levels than toward normal cardiac cells and exhibited a favourable therapeutic index as per a cytokine release assay. Thus, TPP-45142, with an improved safety profile, is a promising next-generation TCE for treating challenging HER2-low cancers.
- Sanofi (Belgium) Ghent India.
Organizational Affiliation:
